Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Liver Unit, Hospital Clinic Barcelona. IDIBAPS. Liver and Digestive Diseases Networking Biomedical Research Centre (CIBERehd). University of Barcelona. Spain.
J Hepatol. 2024 Aug;81(2):326-344. doi: 10.1016/j.jhep.2024.04.007. Epub 2024 Jun 6.
Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can be cured in almost all infected patients. This has led to a number of clinical questions regarding the optimal management of the millions of patients cured of HCV. This position statement provides specific guidance on the appropriate follow-up after a sustained virological response in patients without advanced fibrosis, those with compensated advanced chronic liver disease, and those with decompensated cirrhosis. Guidance on hepatocellular carcinoma risk assessment and the management of extrahepatic manifestations of HCV is also provided. Finally, guidance is provided on the monitoring and treatment of reinfection in at-risk patients. The recommendations are based on the best available evidence and are intended to help healthcare professionals involved in the management of patients after treatment for HCV.
随着直接作用抗病毒药物（DAAs）的出现，几乎所有感染 HCV 的患者都可以治愈。这就引出了许多关于治愈 HCV 的数百万患者的最佳管理的临床问题。本立场声明就无肝硬化或代偿期肝硬化和失代偿期肝硬化患者的 HCV 患者在获得持续病毒学应答后的适当随访提供了具体的指导意见。还就肝癌风险评估和 HCV 肝外表现的管理提供了指导意见。最后，就高危患者的再感染监测和治疗提供了指导意见。这些建议是基于现有的最佳证据，旨在帮助参与 HCV 治疗后患者管理的医疗保健专业人员。
